Navigation Links
PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Date:3/24/2008

ANNAPOLIS, Md., March 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the year ended 2007 will be released on Monday, March 31, 2008.

PharmAthene management will be hosting a conference call to discuss its year end financial results. The call is scheduled to begin at 4:30 p.m. Eastern Time on Monday, March 31, 2008 and will last approximately 30 minutes.

The dial-in number within the United States is 866-700-6979. The dial-in number for international callers is 617-213-8836. The participant passcode is 29363875.

A replay of the conference call will be available for 30 days, beginning at approximately 6:30 p.m. Eastern Time March 31, 2008 until approximately 11:50 p.m. Eastern Time April 30, 2008. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 76157985.

The conference call will also be webcast and can be accessed from the company's website at http://www.PharmAthene.com. A link to the webcast may be found on both the Home Page and also under the Investor Relations section of the website. The webcast will be available for 30 days, or until April 30, 2008.

About PharmAthene, Inc

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene to Delay Release of Full Year 2007 Financial Results
2. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
3. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
4. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
5. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
6. PharmAthene to Present at the BIO CEO & Investor Conference 2008
7. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
8. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
9. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
10. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... LEXINGTON, Ky. (PRWEB) , ... March 30, 2020 ... ... the launch of its latest product, ArmourGuard® RTU, an EPA-approved spray-on antimicrobial solution. ... the only biosecurity solution that provides continual antimicrobial activity against microorganisms for up ...
(Date:3/27/2020)... ... March 25, 2020 , ... ... histopathology laboratory located centrally in the midwest for high-quality, quick-turn, board-certified reporting. ... a highly motivated, independent, professional team that is focused on incredible quality, ...
(Date:3/12/2020)... ... March 12, 2020 , ... With ... (AFM) technology, increases the business investment in Europe by inaugurating a new scientific ... Opening Ceremony of the new Nanoscience Center Europe took place Tuesday, February 18, ...
(Date:3/4/2020)... ... March 04, 2020 , ... This month, Cognosante will make its annual ... will showcase both expanded and emerging offerings that align with the HIMSS annual theme, ... to be comprehensive, timely, and engaging. From Interoperability and HIE to ...
Breaking Biology Technology:
(Date:3/20/2020)... ... March 20, 2020 , ... ImStem Biotechnology, Inc. (Farmington ... derived mesenchymal stem cells (hES-MSC), through a proprietary method using a trophoblast intermediate ... rare orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) ...
(Date:3/13/2020)... ... March 13, 2020 , ... ... Vivorte Inc. to be the exclusive distributor of the Louisville-based company’s orthobiologics portfolio. ... medical education expertise to distribute Vivorte’s calcium phosphate-based bone allograft (Trabexus) and calcium ...
(Date:3/5/2020)... ... 05, 2020 , ... With numerous products in its pipeline, ... accelerate Cytonus’ existing products and to expand the companies’ intellectual property assets. Cytonus ... company located in Austria. , Phoenestra has developed IP assets in connection ...
Breaking Biology News(10 mins):